Verona Pharma Plc ADR (NASDAQ: VRNA)’s stock price has decreased by -4.17 compared to its previous closing price of 69.14. However, the company has seen a -8.30% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-06 that Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
Moreover, the 36-month beta value for VRNA is 0.19. Analysts have varying opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 74.63M and currently, short sellers hold a 10.42% of that float. On May 09, 2025, VRNA’s average trading volume was 1.44M shares.
VRNA’s Market Performance
VRNA’s stock has seen a -8.30% decrease for the week, with a 22.32% rise in the past month and a 8.18% gain in the past quarter. The volatility ratio for the week is 4.44%, and the volatility levels for the past 30 days are at 5.94% for Verona Pharma Plc ADR The simple moving average for the past 20 days is 2.13% for VRNA’s stock, with a 47.74% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with TD Cowen repeating the rating for VRNA by listing it as a “Buy.” The predicted price for VRNA in the upcoming period, according to TD Cowen is $100 based on the research report published on April 28, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $80. The rating they have provided for VRNA stocks is “Overweight” according to the report published on April 21st, 2025.
ROTH MKM gave a rating of “Buy” to VRNA, setting the target price at $68 in the report published on January 10th of the current year.
VRNA Trading at 3.59% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.68% of loss for the given period.
Volatility was left at 5.94%, however, over the last 30 days, the volatility rate increased by 4.44%, as shares surge +14.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.31% upper at present.
During the last 5 trading sessions, VRNA fell by -8.30%, which changed the moving average for the period of 200-days by +189.60% in comparison to the 20-day moving average, which settled at $64.88. In addition, Verona Pharma Plc ADR saw 42.68% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Rickard Kathleen A., who sale 114,984 shares at the price of $8.82 back on May 06 ’25. After this action, Rickard Kathleen A. now owns 2,546,472 shares of Verona Pharma Plc ADR, valued at $1,014,343 using the latest closing price.
KATHLEEN RICKARD, the Officer of Verona Pharma Plc ADR, proposed sale 14,373 shares at $72.25 during a trade that took place back on May 06 ’25, which means that KATHLEEN RICKARD is holding shares at $1,038,449 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -1.16 for the present operating margin
- 0.95 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -1.38. The total capital return value is set at -0.29. Equity return is now at value -72.73, with -40.26 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -56.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -11.7.
Currently, EBITDA for the company is -142.19 million with net debt to EBITDA at 2.27. When we switch over and look at the enterprise to sales, we see a ratio of 44.22. The receivables turnover for the company is 1.91for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.86.
Conclusion
To wrap up, the performance of Verona Pharma Plc ADR (VRNA) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
